相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Antiemetics: ASCO Guideline Update
Paul J. Hesketh et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Evaluation of antiemetic practices for prevention of chemotherapy-induced nausea and vomiting (CINV): results of a European oncology nurse survey
Pascale Dielenseger et al.
SUPPORTIVE CARE IN CANCER (2019)
Crossover safety study of aprepitant: 2-min injection vs 30-min infusion in cancer patients receiving emetogenic chemotherapy
Rudolph M. Navari et al.
ONCOTARGETS AND THERAPY (2019)
HTX-019 via 2-min injection or 30-min infusion in healthy subjects
Thomas Ottoboni et al.
FUTURE ONCOLOGY (2019)
Infusion reactions following administration of intravenous rolapitant at an academic medical center
Amanda S. Cass et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2019)
Chemotherapy-induced nausea and vomiting (CINV) and adherence to antiemetic guidelines: results of a survey of oncology nurses
Rebecca Clark-Snow et al.
SUPPORTIVE CARE IN CANCER (2018)
Safety of Polysorbate 80 in the Oncology Setting
Lee S. Schwartzberg et al.
ADVANCES IN THERAPY (2018)
Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic chemotherapy
L. Schwartzberg et al.
ANNALS OF ONCOLOGY (2018)
A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC)
L. Zhang et al.
ANNALS OF ONCOLOGY (2018)
Infusion site adverse events in breast cancer patients receiving highly emetic chemotherapy with prophylactic anti-emetic treatment with aprepitant and fosaprepitant: A retrospective comparison
Takashi Tsuda et al.
MOLECULAR AND CLINICAL ONCOLOGY (2016)
Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial
Lee S. Schwartzberg et al.
LANCET ONCOLOGY (2015)
Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials
Bernardo L. Rapoport et al.
LANCET ONCOLOGY (2015)
An analysis of fosaprepitant-induced venous toxicity in patients receiving highly emetogenic chemotherapy
Livia T. Hegerova et al.
SUPPORTIVE CARE IN CANCER (2015)
Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study
P. J. Hesketh et al.
ANNALS OF ONCOLOGY (2014)
A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy
M. Aapro et al.
ANNALS OF ONCOLOGY (2014)
Molecular mechanisms of 5-HT3 and NK1 receptor antagonists in prevention of emesis
Camilo Rojas et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2014)
Aprepitant triple therapy for the prevention of chemotherapy-induced nausea and vomiting following high-dose cisplatin in Chinese patients: a randomized, double-blind, placebo-controlled phase III trial
Zhihuang Hu et al.
SUPPORTIVE CARE IN CANCER (2014)
Fosaprepitant-induced phlebitis: a focus on patients receiving doxorubicin/cyclophosphamide therapy
A. D. Leal et al.
SUPPORTIVE CARE IN CANCER (2014)
Highly Frequent and Enhanced Injection Site Reaction Induced by Peripheral Venous Injection of Fosaprepitant in Anthracycline-Treated Patients
Yumiko Sato et al.
JOURNAL OF CANCER (2014)
Antiemetic Guideline Consistency and Incidence of Chemotherapy-Induced Nausea and Vomiting in US Community Oncology Practice: INSPIRE Study
James W. Gilmore et al.
JOURNAL OF ONCOLOGY PRACTICE (2014)
Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial
H. Saito et al.
ANNALS OF ONCOLOGY (2013)
The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER)
M. Aapro et al.
ANNALS OF ONCOLOGY (2012)
Inhibition of substance P-mediated responses in NG108-15 cells by netupitant and palonosetron exhibit synergistic effects
Marigo Stathis et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2012)
Single-Dose Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Cisplatin Therapy: Randomized, Double-Blind Study Protocol-EASE
Steven Grunberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment
H. J. Schmoll et al.
ANNALS OF ONCOLOGY (2006)
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy
DG Warr et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - The Aprepitant Protocol 052 Study Group
PJ Hesketh et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
分享论文
